Preparation Of Anti-CPV Hyperimmune Serum And Observation Of The Curative Effect

At present, CPV-2a and CPV-2b are our popular CPV strains, in which CPV-2a dominates. In order to investigate whether dogs produce high titers of serum antibodies after using CPV-2a alone to immunized and after using CPV-2and CPV-2a combined immune. In this study, select the19dogs as experimental animals, these dogs clinically healthy and well-nourished, as measured by HI CPV negative.Randomly selected9dogs for CPV-2a alone immune, the nine dogs divided into three groups (numbered1,2,3, each group3dogs), followed by three different doses (1mL,2mL,3mL) for three groups of dogs were injected subcutaneously. Each group immunized three times, the first were used inactivated CPV-2a, second and third with virulent CPV-2a, each time interval10d. Another10dogs for CPV-2and CPV-2a combined immune, divided into two groups (numbered A,B, each group5dogs), two groups were injected subcutaneously according to the procedure that is CPV-2/CPV-2/CPV-2a and CPV-2/CPV-2a/CPV-2a, immunized three times at intervals of10d. Each group in the pre-immunization10d,20d,30d,35d and immunized10d,20d,30d,35d blood samples were collected to determine antibody titer, when the serum antibody titer not rise or decline, then carotid blood serum was collected.Then observe the the curative effect of anti-canine parvovirus hyperimmune serum. To attack6experimental dogs with CPV-2a virus,6dogs divided into three groups (numbered a, b, c, each group2dogs), then use the serum collected from the common immune groups A, B and the serum commonly used in clinical to treat the infection dogs at1-2mL/kg dose, daily monitoring of white blood cell changes. Finally therapy the dogs clinical infection CPV and tatistics the cure rate.The results show that, the stability of virulence of the CPV-2a strain is strong, F81cell culture proliferation soon appear obvious CPE. CPV-2a strain directly used for immunization in dogs, not elevated the antibody titer. In different doses of immunization program, the dogs of3mL dose groug soon diseased after the second immunization, only in the2mL dose group the antibody titers increased a Iog2titer, but later at the detection of antibody titer is quickly reduced to the original level, this shows that although the dog is the main host of CPV, but it can not increase the antibody titer with the CPV-2a genotype direct immunofluorescence. The dogs used CPV-2and CPV-2a combined immune, antibody titers were significantly increased. CPV-2and CPV-2a has a certain synergy, the antibody titer of group A reached1:10240, the antibody titer of group B reached1:5120. A significant increase in white blood cells of dogs attack drug after treatment by serum antibodies obtained from the two groups, after the3d the white blood cell regained normal, the effect of two groups both better than commonly used clinical serum. The clinical cure rate of serum antibody obtained from two groups (81.8%and80%), both higher than the cure rate of serum commonly used in the clinical (76.9%), indicates that there are certain synergy in common immune.